The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions.

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY 14.56%). But now, an investment ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Sam Peasah, PhD, MBA, RPh, director of High-Value Health Care Value-Based Pharmacy Initiatives at UPMC Health Plan, discusses ways that health plans can help reduce the cost burden of medications to ...

For individuals living with type 2 diabetes or struggling with weight loss, Rybelsus has become a popular name in the realm of oral GLP-1 receptor agonists. While its effectiveness in lowering blood ...

WEIGHT loss injections have become the holy grail in the fight against obesity, helping people shift the pounds they’ve been ...

My dad, Michael Mosley, was an inspiration to millions of people worldwide – particularly those living with obesity or type 2 ...

A new study has found that 10-hydroxy-cis-12-octadecenoic acid (HYA), a metabolite derived from linoleic acid by gut microbiota, can help reduce ...

These are Lilly's glucagon-like peptide-1 (GLP-1 ... Another opportunity that I'm highly optimistic about is Alzheimer's disease (AD). The AD market is expected to be worth tens of billions ...

The Cambridgeshire, England-based biopharmaceutical company reported a pretax loss of GBP10.6 million in 2024, widened from GBP8.9 million in 2023. Revenue was GBP5.1 million, up 10% from GBP4.6 ...

Slimlex GLP-1 Capsules in Canada. Natural weight loss support, appetite control & metabolic boost. Buy now from the official ...